GlassScriptPhysician profile
Karol Denise Dangaran
NPI 1225062052
$12,613.20
in general payments reported to CMS, 2019-2025
36 companies · $2,221 in 2025
The $2,221 reported for 2025 was more than what 78% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,354 · 2020: $1,005 · 2021: $1,784 · 2022: $1,985 · 2023: $1,661 · 2024: $2,603 · 2025: $2,221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,265 · Education: $208 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,264.62 |
| Education | $208.43 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,202.68 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,382.38 | 2019-2025 | Tremfya, Simponi, Stelara |
| Novartis Pharmaceuticals Corporation | $1,273.45 | 2019-2025 | |
| Leo Pharma INC. | $1,084.57 | 2019-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $870.69 | 2020-2025 | |
| Galderma Laboratories, L.P. | $728.34 | 2019-2025 | Nemluvio, Aklief |
| Lilly USA, LLC | $722.34 | 2019-2025 | Taltz, Olumiant, Zepbound |
| Pfizer INC. | $721.52 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $589.22 | 2019-2024 | Dupixent |
| Amgen INC. | $440.91 | 2020-2025 | Otezla, Otezla |
| Incyte Corporation | $355.36 | 2021-2024 | Opzelura |
| Ucb, INC. | $305.73 | 2024-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $222.22 | 2019-2025 | Ilumya |
| Dermavant Sciences, INC. | $213.73 | 2023-2024 | Vtama |
| Allergan, INC. | $209.85 | 2019-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $183.79 | 2024-2025 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.53 | 2022-2025 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $126.45 | 2019-2023 | Jublia, Arazlo |
| Epi Health, LLC | $106.78 | 2021-2022 | |
| Biofrontera INC. | $103.63 | 2021-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Sanofi-Aventis U.S. LLC | $84.24 | 2021 | |
| Almirall LLC | $59.10 | 2019-2025 | Klisyri |
| Vyne Pharmaceuticals INC. | $55.57 | 2020-2021 | |
| Prugen, INC. Pharmaceuticals | $48.94 | 2019 | |
| Journey Medical Corporation | $47.36 | 2021-2025 | |
| Celgene Corporation | $44.25 | 2019 | |
| Dermira, INC. | $44.10 | 2020-2021 | |
| Sandoz INC. | $39.82 | 2019-2020 | |
| Verrica Pharmaceuticals INC. | $37.30 | 2024 | Ycanth |
| Organon LLC | $36.64 | 2025 | Vtama |
| Janssen Scientific Affairs, LLC | $24.19 | 2021 | |
| Taro Pharmaceuticals USA, INC. | $22.72 | 2019 | |
| Strata Skin Sciences, INC. | $18.22 | 2021 | |
| Aclaris Therapeutics, INC. | $17.22 | 2019 | |
| Arcutis Biotherapeutics, INC. | $14.78 | 2023 | |
| Mindera Corp | $14.58 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karol Dangaran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.